Intrapleural low-molecular-weight urokinase or tissue plasminogen activator versus single-chain urokinase in tetracycline-induced pleural loculation in rabbits
Experimental lung research, 2007•Taylor & Francis
The authors compared the ability of a single dose of the proenzyme single-chain urokinase
(scuPA), low-molecular-weight urokinase, tissue plasminogen activator (tPA), or a mutant
site-inactive scuPA to resolve intrapleural loculations at 72 to 96 hours after tetracycline-
induced pleural injury in rabbits. Both scuPA and tPA reversed loculations at 96 hours after
injury P≤. 001, whereas low-molecular-weight urokinase and the scuPA mutant were
ineffective. scuPA and tPA generated inhibitor complexes, induced fibrinolytic activity, and …
(scuPA), low-molecular-weight urokinase, tissue plasminogen activator (tPA), or a mutant
site-inactive scuPA to resolve intrapleural loculations at 72 to 96 hours after tetracycline-
induced pleural injury in rabbits. Both scuPA and tPA reversed loculations at 96 hours after
injury P≤. 001, whereas low-molecular-weight urokinase and the scuPA mutant were
ineffective. scuPA and tPA generated inhibitor complexes, induced fibrinolytic activity, and …
The authors compared the ability of a single dose of the proenzyme single-chain urokinase (scuPA), low-molecular-weight urokinase, tissue plasminogen activator (tPA), or a mutant site-inactive scuPA to resolve intrapleural loculations at 72 to 96 hours after tetracycline-induced pleural injury in rabbits. Both scuPA and tPA reversed loculations at 96 hours after injury P ≤ .001, whereas low-molecular-weight urokinase and the scuPA mutant were ineffective. scuPA and tPA generated inhibitor complexes, induced fibrinolytic activity, and quenched plasminogen activator-1 activity in pleural fluids. The authors conclude that scuPA reverses loculations as effectively as tPA at clinically applied intrapleural doses, whereas low-molecular-weight urokinase was ineffective.
Taylor & Francis Online